Table 4: Distribution of most significant markers in men and women with PsA according to age at psoriasis onset (cutoff: 40 years). 
(a) PsA females 
 Marker  Age at onset <40: 40  Age at onset >40: 15  Female controls: 55 
 HLAC*06  26 (65%) OR: 9.5 (3.6–24.9),  5 (33%)  9 (16.4%)  HLAC*07  20 (50%) OR: 2.9 (1.2–6.9),  7 (46.7%)  14 (25.5%)  TNF308A  15 (37.5%)  10 (66.7%) OR: 9.0 (2.6–31.2),  12 (22%)  HLADR17  4 (10%)  8 (53%) OR: 5.1 (1.5–17.5),  10 (18%)  MICAA9  25 (62.5%) OR: 3.4 (1.5–8.0),  8 (53.3%)  18 (32.7%)  HLAB*27  12 (30%) OR: 5.5 (1.6–18.5),  3 (20%)  4 (7.3%) 


(b) PsA males 

Marker  Age at onset <40: 45  Age at onset >40: 10  Male controls: 55 
 HLAC*06  26 (58%) OR: 6.2 (2.5–15.2),  5 (50%) OR: 4.5 (1.1–18.5),  10 (18.2%)  MICBCA23  1 (2.2%)  5 (50%) OR: 17.3 (3.2–94.9),  3 (5.5%)  C1_4_4 (384)  12 (26.7%)  8 (80%) OR: 14.3 (2.7–76.6),  12 (22%)  MICAA9  27 (60%) OR: 4 (1.7–9.3),  6 (60%) OR: 4.0 (1.0–16.2),  15 (27.3%)  HLAB*27  19 (42.2%) OR: 9.3 (2.9–30.2),  1 (10%)  4 (7.3%) 

